03347 TIGERMED
- 35.150
- +0.400+1.15%
TIGERMED News
Tiger Pharmaceuticals (03347) plans to spend 500 million to 1 billion yuan to buy back no less than 13.8889 million shares
Tiger Pharmaceuticals (03347) issued an announcement. The company announced on February 6, 2024 and April 12, 2024, respectively...
Tiger Pharmaceuticals (03347) will pay a final dividend of 5.68 yuan for 10 shares on July 31
According to Zhitong Finance App, Tiger Pharmaceuticals (03347) announced that the company will pay a final dividend of 5.68 yuan for 10 shares on July 31, 2024.
泰格醫藥：2023年股東週年大會通告
泰格醫藥：2023年度報告
Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Stock Is Going Strong: Have Financials A Role To Play?
Most readers would already be aware that Hangzhou Tigermed Consulting's (SZSE:300347) stock increased significantly by 31% over the past three months. As most would know, fundamentals are what usual
Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) last week released its latest first-quarter, and things did not turn out so great for shareholders. The analysts look to hav
Trending Industry Today: TIGERMED Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 26th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up and TIGERMED leading Gains.$TIGERMED(03
Changes in Hong Kong stocks | Tiger Pharmaceuticals (03347) rose more than 8% to lead CRO concept stocks, reports say the national level is expected to introduce an action plan for the biological manufacturing industry in the near future
CRO concept stocks increased their gains in the afternoon. As of press release, Tiger Pharmaceuticals (03347) rose 8.39% to HK$33.6; Kanglong Chemical (03759) rose 7.16% to HK$9.43; Pharmaceutical Biotech (02269) rose 6.75% to HK$13.6; and Pharmaceuticals (02359) rose 4.74% to HK$35.35.
Hangzhou Tigermed Consulting's Profit Down 59% in Q1
Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) recorded a 59% decline in attributable profit for the quarter ended March 31 to 235.1 million yuan from 568.5 million yuan during the year-ago perio
Tiger Pharmaceuticals (03347.HK)'s net profit of 235 million yuan in the first quarter decreased by 58.65% year-on-year
On April 25, Ge Longhui (03347.HK) announced that in the first quarter of 2024, the company's operating income was 1.66 billion yuan, a year-on-year decrease of 8.00%; net profit attributable to shareholders of listed companies was 235 million yuan, a year-on-year decrease of 58.65%; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 305 million yuan, a decrease of 20.50% year-on-year.
泰格醫藥：2024年第一季度報告
Zhitong Hong Kong Stock Investment Calendar | April 25
According to Zhitong Finance App statistics, on April 25, 2024, the investment logs of Hong Kong stock listed companies are as follows: Category: Company Performance Announcement Sun Xintian Green Energy Era Electric Dexin China China Aluminum Sanbao Technology Tiger Pharmaceuticals China Shipbuilding Defense Shandong Xinhua Pharmaceutical Co., Ltd. Gloria Ying 21st Century Education Shareholders' Meeting HPC Juice China Lilang HPC Holdings China Lilang HPC HOLDINGS CITIC Construction Investment Securities Tiger Pharmaceuticals Weihai Bank Jinan Industrial dividend payment Tian'an (excluding Clean Day) Kowloon Group (dividend day) Pacific Shipping (dividend day) Pacific Shipping (dividend day) (Excluding clean days) Pacific Shipping (excluding clean days) Remittance
Trending Industry Today: GENSCRIPT BIO Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 19th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending lower today with 9 constituents down and GENSCRIPT BIO leading Losses.$GENS
Changes in Hong Kong stocks | CRO concept stocks continue to decline, the Federal Reserve does not rule out possible interest rate hikes, domestic innovative drugs are still in an adjustment cycle
The Zhitong Finance App learned that CRO concept stocks continued to decline. As of press release, Tiger Pharmaceuticals (03347) fell 7.94% to HK$28.4; Kingsley Biotech (01548) fell 5.93% to HK$10.78; Kanglong Chemical (03759) fell 4.83% to HK$8.47; and Pharmaceuticals (02359) fell 4.5% to HK$32.9. According to the news, overnight, Federal Reserve officials made hawkish remarks. New York Federal Reserve Chairman Williams said that if the data reminds us that we need to raise interest rates to achieve our goals, then we will obviously do it. Furthermore, Asia
Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) fell more than 6%, leading the CRO concept, the possibility that the Federal Reserve will raise interest rates is still possible, and domestic innovative drugs are still in the adjustment cycle
CRO concept stocks continued to decline. As of press release, Zhaoyan Pharmaceutical (06127) fell 5.98% to HK$9.28; Tiger Pharmaceuticals (03347) fell 5.93% to HK$30.15; Kanglong Chemical (03759) fell 5.18% to HK$8.78; and Pharmaceuticals (02359) fell 3.96% to HK$32.75.
Tiger Pharmaceuticals (03347.HK) held a board meeting on April 25 to review and approve the first quarter report
Gelonghui, April 15, 丨 Tiger Pharmaceuticals (03347.HK) announced that the board meeting will be held on April 25, 2024 (Thursday) to review and approve (among other things) the first quarter reports of the company and its subsidiaries for the three months ended March 31, 2024 and/or other issues (if applicable).
TIGERMED: DATE OF BOARD MEETING
Tiger Pharmaceuticals (03347): Adjusting the company's share repurchase plan
Tiger Pharmaceuticals (03347) issued an announcement. The company's board of directors meeting reviewed and approved the “On Adjusting the Company's Share Repurchase Plan...
Solid Earnings May Not Tell The Whole Story For Hangzhou Tigermed Consulting (SZSE:300347)
The recent earnings posted by Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) were solid, but the stock didn't move as much as we expected. However the statutory profit number doesn't tell the wh
Cansino Biotech (06185), the leading healthcare market, surged 15.12%, and Beijing, Guangzhou, and Zhuhai issued pharmaceutical innovation support policies
Jinwu Financial News | The healthcare sector led the market. Hang Seng Healthcare Index rose 1.93%. Among the constituent stocks, Cansino Biotech (06185) rose 15.12%, Junshi Biotech (01877) rose 11.9%, Genting Xinyao (01952) rose 7.8%, Yiming Angke (01541) rose 7.79%, Pharmaceuticals (02268) rose 5.98%, and Tiger Pharmaceuticals (03347) rose 5.8%. According to the news, the Beijing Municipal Medical Security Administration issued “On “Certain Measures to Support the High-Quality Development of Innovative Pharmaceuticals by 9 Departments Including the Beijing Municipal Medical Security Administration” (202
Analysis
Price Target
No Data
